5 completed, 2 terminated, 2 unknown, 1 active not recruiting. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 5, Terminated 2, Unknown 2, Active not recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Anthracyclines: new trials by email Literature Review of Anthracyclines trials Research Report on Anthracyclines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML Entospletinib, Placebo, Cytarabine - Nucleophosmin 1-mutated Acute Myeloid Leukemia | Phase 3 | Terminated | Kronos Bio | 15 | 2021-11-24 | 2024-01-10 |
| NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab - Breast Cancer, Triple Negative Breast Neoplasms | Phase 3 | Active not recruiting | Lund University Hospital | 325 | 2019-12-20 | 2025-09-12 |
| Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer nivolumab, paclitaxel (PTX), nivolumab placebo - Breast Cancer | Phase 3 | Completed | Bristol-Myers Squibb | 521 | 2019-11-18 | 2025-01-08 |
| Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. Midostaurin, Cytarabine, anthracycline ((daunorubicin or idarubicin): Induction Phase only - Acute Myeloid Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 301 | 2018-02-13 | 2024-02-29 |
| Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy paclitaxel/anthracycline - Primary Breast Cancer | Phase 3 | Unknown | Tao OUYANG | 400 | 2011-03-04 | 2021-11-29 |
| Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide, Docetaxel, cyclophosphamide - Breast Cancer | Phase 3 | Terminated | Shanghai Jiao Tong University School of Medicine | 102 | 2009-07-01 | 2016-11-22 |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Anthracyclines, liposomal daunorubicin, 2-CDA - Myeloid Leukemia | Phase 2 / Phase 3 | Unknown | University Hospital Muenster | 550 | 2004-03-01 | 2012-05-23 |
| A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care Azacitidine, Physician Choice - Myelodysplastic Syndromes | Phase 3 | Completed | Celgene | 358 | 2003-11-01 | 2019-10-29 |
| Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine - Breast Cancer | Phase 3 | Completed | National Cancer Center, Korea | 209 | 2002-06-01 | 2011-06-27 |
| Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy Anthracycline/dexamethasone-based induction chemotherapy, Dexamethasone for control of symptoms, Tumor-reduction chemotherapy and stem cell mobilization - Multiple Myeloma | Phase 3 | Completed | WiSP Wissenschaftlicher Service Pharma GmbH | 549 | 2001-08-01 | 2014-11-11 |
Breast Neoplasms (4) · Leukemia, Myeloid, Acute (3) · Leukemia (1) · Leukemia, Myeloid (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Pathologic Complete Response (1) · Triple Negative Breast Neoplasms (1)
Bristol-Myers Squibb (1) · Celgene (1) · Kronos Bio (1) · Lund University Hospital (1) · National Cancer Center, Korea (1) · Novartis Pharmaceuticals (1) · Shanghai Jiao Tong University School of Medicine (1) · Tao OUYANG (1) · University Hospital Muenster (1) · WiSP Wissenschaftlicher Service Pharma GmbH (1)
Czechia (4) · France (4) · Germany (4) · Italy (4) · Spain (4) · China (3) · Hungary (3) · Poland (3) · Sweden (3) · United States (3) · Australia (2) · Brazil (2) · Bulgaria (2) · Canada (2) · Denmark (2)
CL Beach (1) · Christian Straka, Prof. Dr. (1) · Dirk Reinhardt, Prof. Dr. med. (1) · Jungsil Ro, MD,PhD (1) · Kunwei Shen (1) · Niklas Loman, MD, PhD (1) · Tao Ouyang, Doctor (1) · Ursula Creutzig, Prof. Dr. med. (1)
PMID 18083847, PMID 18182574, PMID 19230772, PMID 20026804, PMID 20136825, PMID 20394651, PMID 20451404, PMID 21480469, PMID 23585522, PMID 23704089, PMID 26814618, PMID 27269945, PMID 27662018, PMID 37581981, PMID 38913933, PMID 39838118, PMID 40803346
2016 (1)